GENENTECH, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1976-01-01
- Employees
- 11.1K
- Market Cap
- -
- Website
- http://www.gene.com
A Study of Bevacizumab Plus Carboplatin and Paclitaxel in Subjects With Advanced, Previously Untreated, Squamous Non-Small Cell Lung Cancer (BRIDGE)
Phase 2
Completed
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2006-04-26
- Last Posted Date
- 2010-05-11
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 47
- Registration Number
- NCT00318136
A Study of Omalizumab (Xolair) in Subjects With Moderate to Severe Persistent Asthma (EXTRA)
Phase 3
Completed
- Conditions
- Asthma
- Interventions
- First Posted Date
- 2006-04-14
- Last Posted Date
- 2012-02-09
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 850
- Registration Number
- NCT00314574
A Study of Bevacizumab in Combination With First- or Second-Line Therapy in Subjects With Treated Brain Metastases Due to Non-Squamous NSCLC (PASSPORT)
Phase 2
Completed
- Conditions
- Non-Small Cell Lung CancerBrain Neoplasms
- Interventions
- First Posted Date
- 2006-04-11
- Last Posted Date
- 2023-01-06
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 115
- Registration Number
- NCT00312728
A Study to Evaluate the Safety and Efficacy of Efalizumab in Adult Patients With Plaque Psoriasis Involving the Hands and/or Feet
Phase 4
Completed
- Conditions
- Psoriasis
- First Posted Date
- 2006-04-07
- Last Posted Date
- 2017-02-15
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 75
- Registration Number
- NCT00312026
A Study to Determine the Variability of a 6-Minute Walk Test in Cystic Fibrosis Subjects With Advanced Lung Disease
Completed
- Conditions
- Cystic Fibrosis
- First Posted Date
- 2006-04-06
- Last Posted Date
- 2017-05-16
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 25
- Registration Number
- NCT00311506
Cathflo Activase Pediatric Study
Phase 4
Completed
- Conditions
- Dysfunctional Central Venous Access Devices (CVADS)
- First Posted Date
- 2006-03-28
- Last Posted Date
- 2014-04-09
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 300
- Registration Number
- NCT00307580
A Study to Evaluate Rituximab in Combination With Methotrexate in Methotrexate-Naive Patients With Active Rheumatoid Arthritis
Phase 3
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2006-03-06
- Last Posted Date
- 2017-07-28
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 755
- Registration Number
- NCT00299104
A Study to Evaluate the Safety and Efficacy of Rituximab in Combination With Methotrexate Compared to Methotrexate Alone in Patients With Active Rheumatoid Arthritis
Phase 3
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2006-03-06
- Last Posted Date
- 2017-04-17
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 511
- Registration Number
- NCT00299130
Three-Arm Study of the Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis
- First Posted Date
- 2006-02-07
- Last Posted Date
- 2017-05-22
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 435
- Registration Number
- NCT00287716
- Locations
- 🇺🇸
InterMune, Inc., Brisbane, California, United States
Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis
- First Posted Date
- 2006-02-07
- Last Posted Date
- 2017-04-17
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 344
- Registration Number
- NCT00287729
- Locations
- 🇺🇸
InterMune, Inc., Brisbane, California, United States
© Copyright 2025. All Rights Reserved by MedPath